Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics

Myovant Sciences Ltd. Common Shares (MYOV)

Today's Latest Price: $23.53 USD

1.68 (7.69%)

Updated Nov 27 5:00pm

Add MYOV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MYOV Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MYOV is -0.17 -- better than only 7.14% of US stocks.
  • With a price/sales ratio of 63.95, Myovant Sciences Ltd has a higher such ratio than 96% of stocks in our set.
  • MYOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.91% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Myovant Sciences Ltd are HRTX, ZGNX, CLLS, CAPR, and CKPT.
  • Visit MYOV's SEC page to see the company's official filings. To visit the company's web site, go to

MYOV Stock Price Chart Interactive Chart >

Price chart for MYOV

MYOV Price/Volume Stats

Current price $23.53 52-week high $23.66
Prev. close $21.85 52-week low $5.98
Day low $21.99 Volume 598,309
Day high $23.66 Avg. volume 1,049,570
50-day MA $17.17 Dividend yield N/A
200-day MA $15.10 Market Cap 2.13B

Myovant Sciences Ltd. Common Shares (MYOV) Company Bio

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.

MYOV Latest News Stream

Event/Time News Detail
Loading, please wait...

MYOV Latest Social Stream

Loading social stream, please wait...

View Full MYOV Social Stream

Latest MYOV News From Around the Web

Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.

Investors skittish with Myovant Sciences after relugolix fails to top comparator drug on key survival endpoint in prostate cancer study

Myovant Sciences' (MYOV) post-COVID-selloff rally came to an abrupt end on Tuesday, September 29, after it announced results on another secondary endpoint from the Phase 3 HERO clinical trial evaluating relugolix in men with advanced androgen-sensitive prostate cancer.Investors reacted strongly to the miss on castration resistance-free survival ((CRFS)) through week 48....

Seeking Alpha | October 3, 2020

Myovant Sciences' relugolix triplet therapy shows positive action in uterine fibroid study

Myovant Sciences (MYOV) presents one-year data on bone mineral density ((BMD)) from the Phase 3 LIBERTY program evaluating the safety and efficacy of once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids.LIBERTY 1 and LIBERTY 2 met the...

Seeking Alpha | September 14, 2020

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic womenDetailed data from ovulation.

Yahoo | July 6, 2020

Myovant Sciences Ltd. (MYOV): Hedge Fund Sentiment Unchanged

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 6, 2020

Goldman Sachs: There’s an Opportunity Brewing in These 3 Stocks

The COVID-19 pandemic has decimated the U.S. economy, yet the stock market is alive and well. Against the backdrop of a recession, the market actually had its strongest quarter in over 20 years, with the S&P 500 notching its largest quarterly gain since the last quarter of 1998, surging 20%. As for the NASDAQ, it climbed 31% higher during the quarter, marking its best quarterly performance since Q4 1999.While certainly volatile, the quarter saw investors take an optimistic approach due to reopening efforts and unprecedented stimulus packages. That being said, going forward into Q3, plenty of uncertainty is lingering over Wall Street. So, how are investors supposed to lock in on compelling plays? The Street’s pros can provide some much-needed inspiration, namely those from investment fir...

Yahoo | July 1, 2020

Read More 'MYOV' Stories Here

MYOV Price Returns

1-mo 58.13%
3-mo 18.54%
6-mo 38.98%
1-year 32.12%
3-year 76.25%
5-year N/A
YTD 51.61%
2019 -5.42%
2018 29.83%
2017 1.61%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7532 seconds.